FBXW2 localizes with osteocalcin in bovine periosteum on culture dishes as visualized by double immunostaining

Mari Akiyama

Department of Biomaterials, Osaka Dental University, 8-1, Kuzuhahanozono-cho, Hirakata-shi, Osaka 573-1121, Japan

* Corresponding author.
E-mail address: mari@cc.osaka-dent.ac.jp (M. Akiyama).

Abstract

Osteocalcin (OC) is a well-known protein related to bone, however, the role of F-box and WD-40 domain-containing protein 2 (FBXW2) in bone remains unclear. In 2016, the presence of FBXW2 in bovine periosteum was reported. In this study, double immunostaining was used to investigate the relationship between OC and FBXW2. FBXW2 showed tubular structures, and OC showed a similar localization pattern as FBXW2. Double immunostaining findings suggested that FBXW2 tubes were coated with OC. To the author’s knowledge, this is the first study to reveal the interaction between OC and FBXW2.

Keywords: Biochemistry, Cell biology, Structural biology

1. Introduction

Osteocalcin (OC) is involved in bone regeneration. However, the role of F-box and WD-40 domain-containing protein 2 (FBXW2) is unknown. Paraffin sections of bovine periosteum were prepared after 5 weeks of culture. Immunostaining
confirmed that OC and FBXW2 are expressed in the bovine periosteum. However, the relationship between these proteins is unclear. Double immunostaining showed that FBXW2 has a tubular structure and that OC is present on the perimeter of FBXW2-containing tubes. This study suggests that FBXW2 localizes with OC on culture dishes.

F-box proteins promote the ubiquitin-proteasome system (Halbach et al., 2015; Murdoch et al., 2016; Sandoval et al., 2015; Teixeira et al., 2013; Trausch-Azar et al., 2015; Yalla et al., 2018; Zheng et al., 2016) and interact with cell cycle progression (Randle and Laman, 2016; Zhang et al., 2017). One F-box protein, FBXW2, has been identified as a housekeeping gene (Almeida et al., 2014), but the functions of FBXW2 are largely unknown. FBXW2 is expressed in placenta cells (Chiang et al., 2008; Wang et al., 2013) and lung cancer cell lines and tissue (Xu et al., 2017). A combination of mass spectrometry and immunohistochemistry has been used to analyze proteins expressed in periosteum tissue and cultured periosteum-derived cells, and FBXW2 expression has been confirmed along with other proteins (Akiyama, 2014a, 2014b, 2016). A previous study by Akiyama showed that FBXW2 is expressed in periosteum tissue (Akiyama, 2016). Periosteum tissue and cultured periosteum-derived cells are known to possess osteogenic ability (Li et al., 2016; Sung et al., 2015), and they have been studied in bone regeneration (Akiyama et al., 2006; Akiyama and Nakamura, 2009). The histology of the periosteum has been widely studied (Duchamp de Lageneste et al., 2018; Fan et al., 2010; Ferretti and Mattioli-Belmonte, 2014; Kim et al., 2016; Roberts et al., 2015) as either the periosteum in living bodies or immediately fixed tissue after death. Additionally, Akiyama (2016) studied periosteum tissue containing periosteum-derived cells after 5 weeks of culture on dishes.

Immunohistochemistry was previously performed using single staining (Akiyama, 2014a, 2014b, 2016), but immunostaining using more than one antibody in the same tissue has been used to characterize protein interactions (Isidro et al., 2015; Rozenvald et al., 2017). In this study, double immunohistochemistry was performed in order to determine the potential interaction between OC and FBXW2. The findings showed that both FBXW2 and OC were expressed in periosteum tissue. Furthermore, OC appeared to coat FBXW2 tubes.

2. Materials and methods

2.1. Periosteum extraction and section preparation

Periosteum tissue and sections were obtained as described previously (Akiyama, 2014b). The periosteum was removed from bovine legs (Kobe Chuo Chikusan, Kobe, Japan) at 24 h after death. All protocols were approved by Osaka Dental University animal experiments committee (approval number 17-02015) and
complied with fundamental guidelines for proper conduct of animal experiment and related activities in academic research institutions under the jurisdiction of the Ministry of Education, Culture, Sports, Science and Technology (the Ministry of Education, Culture, Sports, Science and Technology directive 2006, Notice No. 71). To obtain periosteum-derived cells, the periosteum was used for explant culture on dishes with 10 ml Medium 199 (Gibco by Life Technologies, Grand Island, NY, USA) supplemented with ascorbic acid for 5 weeks. Both the periosteum and periosteum-derived cells were fixed in 4% paraformaldehyde, and paraffin blocks were prepared.

2.2. Double immunostaining

Three primary antibodies were used: anti-FBXW2 antibody (1:100, ab5309; Abcam, Cambridge, UK), anti-exosome complex component RRP45 (EXOSC9) (1:200, H-300 for 300 human amino acids; sc-135118; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), and anti-osteocalcin (1:500, code no. M042, clone no. OCG2; Takara Bio Inc., Otsu, Japan). Anti-human procollagen type 1 c-peptide (PIP) (1:500, code no. M011, clone no. PC5-5; Takara Bio Inc.) and anti-Rho GTPase activating protein 36 (ARHGAP36) (1:100, D-14; sc-138596; Santa Cruz Biotechnology, Inc.) were used as negative controls. Anti-EXOSC9 antibody was reported to stain cell nuclei of bovine periosteum-derived cells (Akiyama, 2014b). Three secondary antibodies were used: mouse anti-goat IgG-AP (1:200, sc-2355; Santa Cruz Biotechnology, Inc.) with anti-FBXW2 antibody; N-Histo Simple Stain AP (R) (#414251, Nichirei Biosciences Inc., Tokyo, Japan) with anti-EXOSC9, and N-Histo Simple Stain AP (M) (#414241, Nichirei Biosciences Inc.) with anti-osteocalcin. PermaRed/AP (Diagnostic BioSystems, Pleasanton, CA, USA) and PermaBlue/AP (Diagnostic BioSystems) were used for visualization. Antigens in sections were activated with proteinase K (Dako Cytomation, Glostrup, Denmark).

Four double immunostaining procedures were carried out:

A. OC (blue) + EXOSC9 (red)
B. PIP (negative control; blue) + EXOSC9 (red)
C. OC (red) + FBXW2 (blue)
D. OC (red) + no FBXW2 (antibody diluent; blue)

Single immunostaining with FBXW2 was performed as previously described (Akiyama, 2016) and stained with 3,3’-diaminobenzidine tetrahydrochloride (DAB; brown color). ARHGAP36 was set as a negative control of FBXW2 immunostaining. Finally, hematoxylin counterstaining was performed.
3. Results

Akiyama reported that FBXW2 is expressed in the bovine periosteum (Akiyama, 2016) and recently found that FBXW2 forms tubular structures (Fig. 1a). The diameter of the tubular structures (arrows) was 1–2 microns. While FBXW2 expression was distinct in the periosteum after 5 weeks of culture (Fig. 1a), FBXW2 expression in bone and periosteum on day 0 was faint (Fig. 1b, c). Tubular structures were restricted to between the bone and periosteum, and parts of the tubular structure entered into the bone from the periosteum (Fig. 1b, c). FBXW2 peptide blocked reaction (Fig. 1d, e). Figure 2a, b shows a comparison of OC and FBXW2 staining. In Fig. 2a, double immunostaining of OC (blue) and EXOSC9 (red) coincidently revealed areas of dense OC expression (arrows) and widespread OC expression in the periosteum. As both OC and FBXW2 were expressed in the periosteum, the relationship between OC and FBXW2 was subsequently investigated. In Fig. 2b, double immunostaining of OC (red) and FBXW2 (blue) revealed similar localization patterns for OC and FBXW2. Fig. 3a (condition A) shows outlined tubular structures of OC (blue). Fig. 3b (condition B) shows PIP (blue) did not form tubular structures. In

**Fig. 1.** (a) FBXW2 in bovine periosteum after 5 weeks of culture with periosteum-derived cells. FBXW2 immunostaining was previously reported in 2016 (Akiyama, 2016), but Fig. 1a is a unique image. (b) FBXW2 in bovine bone (day 0), (c) FBXW2 in bovine periosteum (day 0), (d) with FBXW2 antibody, (e) with FBXW2 peptide. Arrows: tubular structure of FBXW2, B: bone, P: periosteum. Scale bar: 100 μm.
Fig. 2. Comparison of OC and FBXW2 localization. Both OC and FBXW2 showed similar staining patterns. Arrows: OC.

Fig. 3. (a, b) Double immunostaining under conditions A and B. (a) OC: blue + EXOSC9; red. (b) PIP (negative control): blue + EXOSC9; red. Scale bar: 100 μm.
Figure 3a, b EXOSC9 (red) expression was observed in periosteum cell nuclei. Figure 4a—d shows the comparison of OC and FBXW2 localization. Figure 4a, c (condition C) showed that OC (red) is present on the perimeter of tubular structures of FBXW2 (blue). Figure 4b, d (condition D) showed that, because OC was thinly deposited, OC expression in condition C was indistinct. ARHGAP36 did not form tubular-shaped structures (Fig. 4e).

4. Discussion

In this study, the potential interaction between OC and FBXW2 were investigated using double immunostaining. The host species of antibodies against OC, EXOSC9, and FBXW2 are mouse, rabbit, and goat, respectively, which prevented potential unexpected interactions (Isidro et al., 2015). OC and PIP antibodies are mouse monocular IgG1 and were diluted 1:500. As in condition B, PIP did not express tubular structures and was thus used as a negative control. FBXW2 and ARHGAP36 antibodies are polyclonal goat IgG and were diluted 1:100. ARHGAP36 was also used as a negative control. For double immunostaining using EXOSC9, OC and EXOSC9 were stained in different ways to show the difference between OC and EXOSC9 staining (Fig. 3a). In conditions A, C, D, OC staining was carried out first as the

![Fig. 4. (a–e) Double immunostaining under conditions C and D. (a, c) OC: red + FBXW2: blue. (b, d) OC: red + no FBXW2: blue. (e) ARHGAP36 (negative control). Scale bar: 100 μm.](image-url)
OC outline was very thin. Although previous reports on single immunostaining of OC, EXOSC9, and FBXW2 utilized horseradish peroxidase (HRP) labeling and DAB staining (Akiyama, 2014b, 2016), we utilized alkaline phosphatase (AP) labeling to improve sensitivity in paraffin sections (Rozenvald et al., 2017). FBXW2 expression was weak and restricted to a specific area immediately after bovine death. In addition, FBXW2 localized between the bone and periosteum with some tubes entering the bone (Fig. 1b, c). FBXW2 staining subsequently increased after 5 weeks of culture.

Figs. 1a, 3a, and 4a–d show that FBXW2 and OC have similar tubular shapes. Based on the findings of this study, FBXW2 tubes appear to be coated with OC around OC-positive areas (Fig. 5). The interaction between OC and other proteins, particularly during glucose metabolism, has been studied (Garbossa and Folli, 2017; Kanazawa, 2015, 2017; Levinger et al., 2017; Liu et al., 2015; Takeno et al., 2018; Thomas et al., 2017), whereas the interaction between OC and FBXW2 has not been previously studied. To the author’s knowledge, this is the first study to reveal an interaction between OC and FBXW2. Future clarification of the roles of OC and FBXW2 in bone regeneration is considered necessary.

5. Conclusions

1. FBXW2 formed tubular structures in the periosteum.
2. OC also formed tubular structures and OC and FBXW2 exhibited the same expression pattern.
3. FBXW2 tubes were coated with OC.
Declarations

Author contribution statement

Mari Akiyama: Conceived and designed the experiments; Performed the experiments; Analyzed and interpreted the data; Contributed reagents, materials, analysis tools or data; Wrote the paper.

Funding statement

This work was supported by Japan Society for the Promotion of Science (JSPS), Japan Grant-in-Aid for Scientific Research (KAKENHI) ((C)26462986).

Competing interest statement

The author declares no conflict of interest.

Additional information

No additional information is available for this paper.

Acknowledgements

The author would like to thank Kobe Chuo Chikusan for providing the bovine legs, KAC Co., Ltd. for serial sections and Dr. Wato Masahiro at Osaka Dental University for helpful discussions. This study was performed at the Institute of Dental Research, Osaka Dental University (Dental Bioscience Facilities). I dedicate this study to the memory of Shizuko Akiyama.

References

Akiyama, M., 2014a. Association of β-tubulin, F-box/leucine-rich repeat protein 14, and type 1 procollagen C-peptide in bovine periosteal cells. Curr. Tissue Eng. 3, 2–6 (discontinued).

Akiyama, M., 2014b. Identification of UACA, EXOSC9, and TMX2 in bovine periosteal cells by mass spectrometry and immunohistochemistry. Anal. Bioanal. Chem. 406, 5805–5813.

Akiyama, M., 2016. Characterization of the F-box proteins FBXW2 and FBXL14 in the initiation of bone regeneration in transplants given to nude mice. Curr. Tissue Eng. (discontinued).

Akiyama, M., Nakamura, M., 2009. Bone regeneration and neovascularization processes in a pellet culture system for periosteal cells. Cell Transpl. 18, 443–452.
Akiyama, M., Nonomura, H., Kamil, S.H., Ignotz, R.A., 2006. Periosteal cell pellet culture system: a new technique for bone engineering. Cell Transpl. 15, 521–532.

Almeida, T.A., Quispe-Ricalde, A., Montes de Oca, F., Foronda, P., Hernandez, M.M., 2014. A high-throughput open-array qPCR gene panel to identify housekeeping genes suitable for myometrium and leiomyoma expression analysis. Gynecol. Oncol. 134, 138–143.

Chiang, M.H., Chen, L.F., Chen, H., 2008. Ubiquitin-conjugating enzyme UBE2D2 is responsible for FBXW2 (F-box and WD repeat domain containing 2)-mediated human GCM1 (glial cell missing homolog 1) ubiquitination and degradation. Biol. Reprod. 79, 914–920.

Duchamp de Lageneste, O., Julien, A., Abou-Khalil, R., Frangi, G., Carvalho, C., Cagnard, N., Cordier, C., Conway, S.J., Colnot, C., 2018. Periosteum contains skeletal stem cells with high bone regenerative potential controlled by Periostin. Nat. Commun. 9, 773.

Fan, W., Bouwense, S.A., Crawford, R., Xiao, Y., 2010. Structural and cellular features in metaphyseal and diaphyseal periosteum of osteoporotic rats. J. Mol. Histol. 41, 51–60.

Ferretti, C., Mattioli-Belmonte, M., 2014. Periosteum derived stem cells for regenerative medicine proposals: boosting current knowledge. World J. Stem Cells 6, 266–277.

Garbossa, S.G., Folli, F., 2017. Vitamin D, sub-inflammation and insulin resistance. A window on a potential role for the interaction between bone and glucose metabolism. Rev. Endocr. Metab. Disord. 18, 243–258.

Halbach, M.V., Stehning, T., Damrath, E., Jendrach, M., Sen, N.E., Basak, A.N., Auburger, G., 2015. Both ubiquitin ligases FBXW8 and PARK2 are sequestrated into insolubility by ATXN2 PolyQ expansions, but only FBXW8 expression is dysregulated. PLoS One 10, e0121089.

Isidro, R.A., Isidro, A.A., Cruz, M.L., Hernandez, S., Appleyard, C.B., 2015. Double immunofluorescent staining of rat macrophages in formalin-fixed paraffin-embedded tissue using two monoclonal mouse antibodies. Histochem. Cell Biol. 144, 613–621.

Kanazawa, I., 2015. Osteocalcin as a hormone regulating glucose metabolism. World J. Diabetes 6, 1345–1354.

Kanazawa, I., 2017. Interaction between bone and glucose metabolism [Review]. Endocr. J. 64, 1043–1053.
Kim, Y.K., Nakata, H., Yamamoto, M., Miyasaka, M., Kasugai, S., Kuroda, S., 2016. Osteogenic potential of mouse periosteum-derived cells sorted for CD90 in vitro and in vivo. Stem Cells Transl. Med. 5, 227–234.

Levinger, I., Brennan-Speranza, T.C., Zulli, A., Parker, L., Lin, X., Lewis, J.R., Yeap, B.B., 2017. Multifaceted interaction of bone, muscle, lifestyle interventions and metabolic and cardiovascular disease: role of osteocalcin. Osteoporos. Int. 28, 2265–2273.

Li, N., Song, J., Zhu, G., Li, X., Liu, L., Shi, X., Wang, Y., 2016. Periosteum tissue engineering-a review. Biomater. Sci. 4, 1554–1561.

Liu, D.M., Guo, X.Z., Tong, H.J., Tao, B., Sun, L.H., Zhao, H.Y., Ning, G., Liu, J.M., 2015. Association between osteocalcin and glucose metabolism: a meta-analysis. Osteoporos. Int. 26, 2823–2833.

Murdoch, J.D., Rostosky, C.M., Gowrisankaran, S., Arora, A.S., Soukup, S.F., Vidal, R., Capece, V., Freytag, S., Fischer, A., Verstreken, P., Bonn, S., Raimundo, N., Milosevic, I., 2016. Endophilin-a deficiency induces the Foxo3a-Fbxo32 network in the brain and causes dysregulation of autophagy and the ubiquitin-proteasome system. Cell Rep. 17, 1071–1086.

Randle, S.J., Laman, H., 2016. F-box protein interactions with the hallmark pathways in cancer. Semin. Cancer Biol. 36, 3–17.

Roberts, S.J., van Gastel, N., Carmeliet, G., Luyten, F.P., 2015. Uncovering the periosteum for skeletal regeneration: the stem cell that lies beneath. Bone 70, 10–18.

Rozenvald, I.B., Richardson, M.D., Brock, L., Maiese, R.L., 2017. Immunohistochemical detection of hairy cell leukemia in paraffin sections: the role of Pax5 and CD103 double staining to improve specificity and sensitivity. Arch. Pathol. Lab. Med. 141, 837–840.

Sandoval, D., Hill, S., Ziemba, A., Lewis, S., Kuhlman, B., Kleiger, G., 2015. Ubiquitin-conjugating enzyme Cdc34 and ubiquitin ligase Skp1-cullin-F-box ligase (SCF) interact through multiple conformations. J. Biol. Chem. 290, 1106–1118.

Sung, I.Y., Park, B.C., Hah, Y.S., Cho, H.Y., Yun, J.W., Park, B.W., Kang, Y.H., Kim, H.C., Hwang, S.C., Rho, G.J., Kim, U.K., Woo, D.K., Oh, S.H., Byun, J.H., 2015. FOXO1 is involved in the effects of cigarette smoke extract on osteoblastic differentiation of cultured human periosteum-derived cells. Int. J. Med. Sci. 12, 881–890.

Takeno, A., Kanazawa, I., Notsu, M., Tanaka, K.I., Sugimoto, T., 2018. Glucose uptake inhibition decreases expressions of receptor activator of nuclear factor-
kappa B ligand (RANKL) and osteocalcin in osteocytic MLO-Y4-A2 cells. Am. J. Physiol. Endocrinol. Metab. 314, E115–E123.

Teixeira, F.R., Manfioli, A.O., Soares, C.S., Baqui, M.M., Koide, T., Gomes, M.D., 2013. The F-box protein FBXO25 promotes the proteasome-dependent degradation of ELK-1 protein. J. Biol. Chem. 288, 28152–28162.

Thomas, C.J., Cleland, T.P., Zhang, S., Gundberg, C.M., Vashishth, D., 2017. Identification and characterization of glycation adducts on osteocalcin. Anal. Biochem. 525, 46–53.

Trausch-Azar, J.S., Abed, M., Orian, A., Schwartz, A.L., 2015. Isoform-specific SCF(Fbw7) ubiquitination mediates differential regulation of PGC-1alpha. J. Cell. Physiol. 230, 842–852.

Wang, C.C., Lo, H.F., Lin, S.Y., Chen, H., 2013. RACK1 (receptor for activated C-kinase 1) interacts with FBW2 (F-box and WD-repeat domain-containing 2) to up-regulate GCM1 (glial cell missing 1) stability and placental cell migration and invasion. Biochem. J. 453, 201–208.

Xu, J., Zhou, W., Yang, F., Chen, G., Li, H., Zhao, Y., Liu, P., Li, H., Tan, M., Xiong, X., Sun, Y., 2017. The beta-TrCP-FBXW2-SKP2 axis regulates lung cancer cell growth with FBXW2 acting as a tumour suppressor. Nat. Commun. 8, 14002.

Yalla, K., Elliott, C., Day, J.P., Findlay, J., Barratt, S., Hughes, Z.A., Wilson, L., Whiteley, E., Popiolek, M., Li, Y., Dunlop, J., Killick, R., Adams, D.R., Brandon, N.J., Houslay, M.D., Hao, B., Baillie, G.S., 2018. FBXW7 regulates DISC1 stability via the ubiquitin-proteasome system. Mol. Psychiatry 23, 1278–1286.

Zhang, J., Yang, Z., Ou, J., Xia, X., Zhi, F., Cui, J., 2017. The F-box protein FBXL18 promotes glioma progression by promoting K63-linked ubiquitination of Akt. FEBS Lett. 591, 145–154.

Zheng, N., Wang, Z., Wei, W., 2016. Ubiquitination-mediated degradation of cell cycle-related proteins by F-box proteins. Int. J. Biochem. Cell Biol. 73, 99–110.